How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
39
SWTX Quote, Financials, Valuation and Earnings
Last price:
$37.10
Seasonality move
:
4.38%
Day range:
$36.20 - $37.38
52-week range:
$28.21 - $53.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.53x
P/B ratio:
5.14x
Volume:
286.2K
Avg. volume:
1.2M
1-year change:
2.63%
Market cap:
$2.7B
Revenue:
$5.4M
EPS (TTM):
-$3.89
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$55.1M | -$0.76 | 948.89% | -55.59% | $68.13 |
|
BPMC
Blueprint Medicines
|
$127.5M | -$0.96 | 101.97% | -63.42% | $125.58 |
|
EWTX
Edgewise Therapeutics
|
-- | -$0.37 | -- | -15.68% | $49.43 |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
PTCT
PTC Therapeutics
|
$171.8M | -$1.66 | -37.97% | -75.73% | -- |
|
VRTX
Vertex Pharmaceuticals
|
$2.7B | $4.13 | 10.63% | 10.37% | $493.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$36.81 | $68.13 | $2.7B | -- | $0.00 | 0% | 19.53x |
|
BPMC
Blueprint Medicines
|
$91.62 | $125.58 | $5.8B | -- | $0.00 | 0% | 13.23x |
|
EWTX
Edgewise Therapeutics
|
$29.66 | $49.43 | $2.8B | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.57 | -- | $2.8M | -- | $0.00 | 0% | 0.06x |
|
PTCT
PTC Therapeutics
|
$45.84 | -- | $3.5B | -- | $0.00 | 0% | 3.89x |
|
VRTX
Vertex Pharmaceuticals
|
$408.18 | $493.61 | $105.1B | 25.59x | $0.00 | 0% | 10.00x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
-- | 2.409 | -- | 5.80x |
|
BPMC
Blueprint Medicines
|
55.25% | 2.789 | 6.59% | 3.10x |
|
EWTX
Edgewise Therapeutics
|
-- | -0.011 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
PTCT
PTC Therapeutics
|
-37.06% | 0.081 | 9.99% | 1.99x |
|
VRTX
Vertex Pharmaceuticals
|
-- | 0.893 | -- | 2.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$46M | -$57.9M | -51.38% | -51.38% | -117.52% | -$27.2M |
|
BPMC
Blueprint Medicines
|
$126.3M | -$49M | -23.14% | -50.13% | -29.05% | -$13.7M |
|
EWTX
Edgewise Therapeutics
|
-- | -$40.4M | -- | -- | -- | -$27.9M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PTCT
PTC Therapeutics
|
$185.9M | -$52M | -425.51% | -- | -28.65% | -$87.8M |
|
VRTX
Vertex Pharmaceuticals
|
$2.4B | $1.1B | -2.89% | -2.89% | 44.43% | $1.3B |
SpringWorks Therapeutics vs. Competitors
-
Which has Higher Returns SWTX or BPMC?
Blueprint Medicines has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -43.9%. SpringWorks Therapeutics's return on equity of -51.38% beat Blueprint Medicines's return on equity of -50.13%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M BPMCBlueprint Medicines98.49% -$0.89 $699.7M -
What do Analysts Say About SWTX or BPMC?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand Blueprint Medicines has an analysts' consensus of $125.58 which suggests that it could grow by 37.07%. Given that SpringWorks Therapeutics has higher upside potential than Blueprint Medicines, analysts believe SpringWorks Therapeutics is more attractive than Blueprint Medicines.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 BPMCBlueprint Medicines9 5 1 -
Is SWTX or BPMC More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.419%.
-
Which is a Better Dividend Stock SWTX or BPMC?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or BPMC?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than Blueprint Medicines quarterly revenues of $128.2M. SpringWorks Therapeutics's net income of -$53.5M is higher than Blueprint Medicines's net income of -$56.3M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus 13.23x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M BPMCBlueprint Medicines13.23x -- $128.2M -$56.3M
-
Which has Higher Returns SWTX or EWTX?
Edgewise Therapeutics has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of --. SpringWorks Therapeutics's return on equity of -51.38% beat Edgewise Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M EWTXEdgewise Therapeutics-- -$0.36 -- -
What do Analysts Say About SWTX or EWTX?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand Edgewise Therapeutics has an analysts' consensus of $49.43 which suggests that it could grow by 66.65%. Given that SpringWorks Therapeutics has higher upside potential than Edgewise Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than Edgewise Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 EWTXEdgewise Therapeutics4 0 0 -
Is SWTX or EWTX More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SWTX or EWTX?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or EWTX?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are larger than Edgewise Therapeutics quarterly revenues of --. SpringWorks Therapeutics's net income of -$53.5M is lower than Edgewise Therapeutics's net income of -$34.1M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M EWTXEdgewise Therapeutics-- -- -- -$34.1M
-
Which has Higher Returns SWTX or NBY?
NovaBay Pharmaceuticals has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -49.65%. SpringWorks Therapeutics's return on equity of -51.38% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About SWTX or NBY?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 557.2%. Given that NovaBay Pharmaceuticals has higher upside potential than SpringWorks Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than SpringWorks Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is SWTX or NBY More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock SWTX or NBY?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or NBY?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. SpringWorks Therapeutics's net income of -$53.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns SWTX or PTCT?
PTC Therapeutics has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -54.2%. SpringWorks Therapeutics's return on equity of -51.38% beat PTC Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M PTCTPTC Therapeutics94.49% -$1.39 -$769.2M -
What do Analysts Say About SWTX or PTCT?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand PTC Therapeutics has an analysts' consensus of -- which suggests that it could grow by 28.09%. Given that SpringWorks Therapeutics has higher upside potential than PTC Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 PTCTPTC Therapeutics6 3 1 -
Is SWTX or PTCT More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.101%.
-
Which is a Better Dividend Stock SWTX or PTCT?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or PTCT?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. SpringWorks Therapeutics's net income of -$53.5M is higher than PTC Therapeutics's net income of -$106.7M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus 3.89x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M PTCTPTC Therapeutics3.89x -- $196.8M -$106.7M
-
Which has Higher Returns SWTX or VRTX?
Vertex Pharmaceuticals has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of 37.71%. SpringWorks Therapeutics's return on equity of -51.38% beat Vertex Pharmaceuticals's return on equity of -2.89%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M VRTXVertex Pharmaceuticals85.84% $4.01 $15.6B -
What do Analysts Say About SWTX or VRTX?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.93%. Given that SpringWorks Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe SpringWorks Therapeutics is more attractive than Vertex Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 VRTXVertex Pharmaceuticals17 11 2 -
Is SWTX or VRTX More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.
-
Which is a Better Dividend Stock SWTX or VRTX?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or VRTX?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. SpringWorks Therapeutics's net income of -$53.5M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus 10.00x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M VRTXVertex Pharmaceuticals10.00x 25.59x $2.8B $1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 49.62% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is up 10.88% over the past day.
